A phase I clinical trial has demonstrated that a synthetic vaccine targeting common KRAS mutations is safe and capable of inducing durable immune responses in 90% of study participants at high risk for pancreatic ductal adenocarcinoma (PDAC). Published in Cancer Discovery, the study suggests that the mKRAS-VAX vaccine could serve as a noninvasive strategy to intercept pancreatic cancer before it progresses to advanced, often fatal stages.
Understanding the Role of KRAS Mutations in PDAC
Pancreatic ductal adenocarcinoma is characterized by its aggressive nature and poor five-year survival rates. According to researchers at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, more than 90% of PDAC cases are driven by oncogenic mutations in the KRAS gene. Because the disease often evolves from microscopic precursor lesions—such as pancreatic intraepithelial neoplasia—that are undetectable via standard imaging, early detection remains a significant clinical challenge.
The study, led by Elizabeth Jaffee, MD, FAACR, and Michael G. Goggins, MD, focused on 20 high-risk individuals with hereditary predispositions or radiographic evidence of pancreatic cysts. The goal was to determine if the mKRAS-VAX vaccine could trigger an immune response to prevent the transformation of these lesions into invasive cancer.
Did you know?
Pancreatic cancer recurrence rates can reach up to 80% following standard surgical resection. Researchers are exploring vaccination as a way to provide long-term, noninvasive surveillance for those at high risk.
Vaccine Efficacy and Immune Response Durability
Participants in the trial received the mKRAS-VAX vaccine through a prime-boost strategy, with initial doses at weeks one, three, and five, followed by a boost at week 13. Data published in Cancer Discovery indicate that 90% of the cohort developed mutant-KRAS-specific effector and central memory T-cell responses. Notably, these responses remained detectable in the blood for up to two years post-vaccination.
While the study was not designed to measure clinical efficacy, exploratory results showed that 37.5% of vaccinated participants experienced a reduction or resolution of their pancreatic cysts. In contrast, an unvaccinated cohort with similar clinical characteristics saw a 6.8% rate of cyst reduction. Neeha Zaidi, MD, noted that while these findings are promising, larger studies are required to confirm if the vaccine is directly responsible for these morphological changes in the cysts.
Future Directions for Cancer Interception
The research team at Johns Hopkins is currently enrolling patients for a follow-up trial to assess whether vaccine-induced T cells can infiltrate actual precancerous tissue, rather than just appearing in the peripheral blood. This step is essential to understanding the biological mechanism behind the vaccine’s impact on lesion stability.
According to Jaffee, the primary hurdle for the future of cancer interception is securing funding for larger trials to identify optimal vaccine targets and the most effective timing for administration. The current study serves as the first proof of concept for using vaccines to intercept pancreatic cancer in human patients, providing a foundation for future preventative oncology research.
Pro Tip:
For patients with a family history of pancreatic cancer, genetic counseling and regular surveillance are currently the standard of care.
Frequently Asked Questions
What is mKRAS-VAX?
mKRAS-VAX is an off-the-shelf synthetic long peptide vaccine designed to target the six most common KRAS mutations found in pancreatic cancer and its precursor lesions.
Is this vaccine available to the general public?
No. The vaccine is currently in the early stages of clinical testing. It is only available to participants enrolled in specific research trials at this time.
How long does the immune response last?
According to the phase I study results, the KRAS-specific T-cell responses induced by the vaccine were detectable in the blood for up to two years after the final dose.
Does the vaccine cure pancreatic cancer?
The study evaluates the vaccine as a tool for “interception,” or preventing the development of cancer in high-risk individuals, rather than treating existing, advanced-stage invasive cancer.
Are you interested in learning more about the latest advancements in cancer research? Subscribe to our newsletter for updates on clinical trials and breakthroughs in oncology.
Worth a look